The full report is titled “Efficacy and Tolerability of 3 Non-nucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. A Randomized, Controlled Equivalence Trial.” It is in the 7 October 2014 issue of Annals of Internal Medicine (volume 161, pages 461-471). The authors are J.L. Lennox, R.J. Landovitz, H.J. Ribaudo, I. Ofotokun, L.H. Na, C. Godfrey, D.R. Kuritzkes, M. Sagar, T.T. Brown, S.E. Cohn, G.A. McComsey, F. Aweeka, C.J. Fichtenbaum, R.M. Presti, S.L. Koletar, D.W. Haas, K.B. Patterson, C.A. Benson, B.P. Baugh, R.Y. Leavitt, J.F. Rooney, D. Seekins, and J.S. Currier, for the ACTG A5257 Team.
Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. Ann Intern Med. 2014;161:I–22. doi: https://doi.org/10.7326/P14-9035
Download citation file:
Published: Ann Intern Med. 2014;161(7):I-22.
HIV, Infectious Disease.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use